Literature DB >> 28258060

Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?

Elad Sharon1.   

Abstract

Champiat and colleagues suggest that a small subset of patients at their center treated with PD1/PDL1 inhibitors appear to exhibit hyperprogression of disease. This commentary goes over some limitations in their preliminary analysis, a possible mechanism to explain the phenomenon, and a means by which other investigators can attempt to validate and further characterize these results. Clin Cancer Res; 23(8); 1879-81. ©2017 AACRSee related article by Champiat et al., p. 1920. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2017        PMID： 28258060      PMCID： PMC7372951          DOI： 10.1158/1078-0432.CCR-16-2926

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  9 in total

1.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

2.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Authors:  Stéphane Champiat; Laurent Dercle; Samy Ammari; Christophe Massard; Antoine Hollebecque; Sophie Postel-Vinay; Nathalie Chaput; Alexander Eggermont; Aurélien Marabelle; Jean-Charles Soria; Charles Ferté
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

3.  Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Authors:  Julia Wilkerson; Kald Abdallah; Charles Hugh-Jones; Greg Curt; Mace Rothenberg; Ronit Simantov; Martin Murphy; Joseph Morrell; Joel Beetsch; Daniel J Sargent; Howard I Scher; Peter Lebowitz; Richard Simon; Wilfred D Stein; Susan E Bates; Tito Fojo
Journal:  Lancet Oncol       Date:  2016-12-13       Impact factor: 41.316

4.  Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Authors:  Krastan B Blagoev; Julia Wilkerson; Wilfred D Stein; James Yang; Susan E Bates; Tito Fojo
Journal:  Cancer Res       Date:  2014-09-01       Impact factor: 12.701

5.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Authors:  Daniel Sanghoon Shin; Jesse M Zaretsky; Helena Escuin-Ordinas; Angel Garcia-Diaz; Siwen Hu-Lieskovan; Anusha Kalbasi; Catherine S Grasso; Willy Hugo; Salemiz Sandoval; Davis Y Torrejon; Nicolaos Palaskas; Gabriel Abril Rodriguez; Giulia Parisi; Ariel Azhdam; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Beata Berent-Maoz; I Peter Shintaku; Dung T Le; Drew M Pardoll; Luis A Diaz; Paul C Tumeh; Thomas G Graeber; Roger S Lo; Begoña Comin-Anduix; Antoni Ribas
Journal:  Cancer Discov       Date:  2016-11-30       Impact factor: 39.397

6.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Authors:  Jianjun Gao; Lewis Zhichang Shi; Hao Zhao; Jianfeng Chen; Liangwen Xiong; Qiuming He; Tenghui Chen; Jason Roszik; Chantale Bernatchez; Scott E Woodman; Pei-Ling Chen; Patrick Hwu; James P Allison; Andrew Futreal; Jennifer A Wargo; Padmanee Sharma
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

7.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Authors:  F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jeffrey S Weber; Adil Daud; Omid Hamid; Amita Patnaik; Antoni Ribas; Caroline Robert; Tara C Gangadhar; Anthony M Joshua; Peter Hersey; Roxana Dronca; Richard Joseph; Darcy Hille; Dahai Xue; Xiaoyun Nicole Li; S Peter Kang; Scot Ebbinghaus; Andrea Perrone; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-03-07       Impact factor: 44.544

8.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Authors:  Charles Ferté; Marianna Fernandez; Antoine Hollebecque; Serge Koscielny; Antonin Levy; Christophe Massard; Rastislav Balheda; Brian Bot; Carlos Gomez-Roca; Clarisse Dromain; Samy Ammari; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

9.  CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease.

Authors:  Shunsuke Sakai; Keith D Kauffman; Michelle A Sallin; Arlene H Sharpe; Howard A Young; Vitaly V Ganusov; Daniel L Barber
Journal:  PLoS Pathog       Date:  2016-05-31       Impact factor: 6.823
  9 in total
  10 in total

1.  Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors:  Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

2.  Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.

Authors:  Michalis Mastri; Christina R Lee; Amanda Tracz; Robert S Kerbel; Melissa Dolan; Yuhao Shi; John M L Ebos
Journal:  Mol Cancer Ther       Date:  2018-04-25       Impact factor: 6.261

3.  A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.

Authors:  Taro Shinozaki; Eri Iwami; Shinnosuke Ikemura; Tatsu Matsuzaki; Takahiro Nakajima; Kazuhiko Hashimoto; Takeshi Terashima
Journal:  BMC Cancer       Date:  2018-05-31       Impact factor: 4.430

4.  Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.

Authors:  Francesco Soria; Andrea I Beleni; David D'Andrea; Irene Resch; Kilian M Gust; Paolo Gontero; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-03-16       Impact factor: 4.226

5.  Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold?

Authors:  Roman Groisberg; Vivek Subbiah
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-06-18

6.  Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft.

Authors:  J Jason Morton; Nathaniel Alzofon; Stephen B Keysar; Tugs-Saikhan Chimed; Julie Reisinger; Loni Perrenoud; Phuong N Le; Cera Nieto; Karina Gomez; Bettina Miller; Randi Yeager; Dexiang Gao; Aik-Choon Tan; Hilary Somerset; Theresa Medina; Xiao-Jing Wang; Jing H Wang; William Robinson; Dennis R Roop; Rene Gonzalez; Antonio Jimeno
Journal:  Mol Cancer Res       Date:  2020-10-21       Impact factor: 6.333

7.  Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.

Authors:  Shisuo Du; Neal McCall; Kyewon Park; Qing Guan; Paolo Fontina; Adam Ertel; Tingting Zhan; Adam P Dicker; Bo Lu
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

8.  Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines.

Authors:  Jason Miska; Jen Bon Lui; Kevin H Toomer; Priyadharshini Devarajan; Xiaodong Cai; JeanMarie Houghton; Diana M Lopez; Maria T Abreu; Gaofeng Wang; Zhibin Chen
Journal:  J Exp Med       Date:  2018-01-26       Impact factor: 14.307

Review 9.  FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Authors:  Nicolas Aide; Rodney J Hicks; Christophe Le Tourneau; Stéphanie Lheureux; Stefano Fanti; Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-05       Impact factor: 9.236

Review 10.  Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.

Authors:  Mikolaj Kocikowski; Katarzyna Dziubek; Maciej Parys
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.